Glycogen synthase kinase 3 (GSK-3) inhibitors: a patent update (2014-2015).
Glycogen synthase kinase (GSK-3) is a serine/threonine kinase that phosphorylates more than one hundred different sequences within proteins in a variety of different pathways. It is a key component of a remarkably large number of cellular processes and diseases. Imbalance of GSK-3 activity is involved in various prevalent pathological diseases, such as diabetes, neurodegenerative diseases and cancer. Understanding its role in different disorders has been central in the last several decades and there has been a significantly large development of GSK-3 inhibitors, some of which, show promising results for the treatment of these devastating diseases. Areas covered: This review covers patent literature on GSK-3 inhibitors and their applications published and/or granted between 2014 and 2015. Expert opinion: GSK-3 inhibitors have gained a prominent role in regenerative medicine based in their ability to modulate stem cells. Moreover, some allosteric modulators of GSK-3 emerge as safe compounds for chronic treatments.
a Centro de Investigaciones Biologicas-CSIC , Translational Medicinal and Biological Chemistry Laboratory , Madrid , Spain.
Valle
V
Palomo
a Centro de Investigaciones Biologicas-CSIC , Translational Medicinal and Biological Chemistry Laboratory , Madrid , Spain.
Ana
A
Martinez
D000818:Animals; D003920:Diabetes Mellitus / Q000188:drug therapy / Q000503:physiopathology; D015195:Drug Design; D004791:Enzyme Inhibitors / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D038362:Glycogen Synthase Kinase 3 / Q000037:antagonists & inhibitors* / Q000378:metabolism; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy / Q000473:pathology; D019636:Neurodegenerative Diseases / Q000188:drug therapy / Q000503:physiopathology; D010330:Patents as Topic; D044968:Regenerative Medicine / Q000379:methods; D013234:Stem Cells / Q000166:cytology / Q000187:drug effects
D004791:Enzyme Inhibitors; D038362:Glycogen Synthase Kinase 3
Alzheimer’s disease; GSK-3 inhibitors; cancer; regenerative medicine; stem cells